Deals In Depth: March 2014
Executive Summary
In a deal worth $139 million, UCB and Sanofi are pursuing anti-inflammatory medications for GI conditions and arthritis; Sterigenics bought isotope maker Nordion for $727 million. Public offerings again drove biopharma financing, making up more than 50% of the $3.4 billion raised; device financing totaled $219 million, with most of the funding from debt and FOPO transactions.
You may also be interested in...
Vision Healthcare Makes Probiotic Play With AixSwiss Acquisition
European dietary supplements online specialist Vision Healthcare has added the Nupure probiotics brand to its portfolio with the acquisition of Netherlands-based AixSwiss.
Lacutamab Data Boost Prospects For Innate Pharma
The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.
Economic Crisis Expected To Shape UK’s Future Drug Pricing Deal
The pharmaceutical industry has warned the UK’s new government about the impact of unprecedented industry payments on medicines supply in the short term and their potential to reduce inward investment in the long term. Along with economic pressures, these considerations will be among the factors forming the backdrop to negotiations on a deal that will determine pricing and access for branded medicines access from 2024 onwards.